ArticleNature communications2018
A CD4-mimetic compound enhances vaccine efficacy against stringent immunodeficiency virus challenge.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 54 citations in OpenAlex.
- Fostemsavir Decreases the Levels of Anti-gp120 CD4-Induced Antibodies in Heavily Treatment-Experienced People With HIV.The Journal of infectious diseases · 2026Article
- CD4-mimetics sensitize HIV-infected cells to ADCC mediated by plasma from persons with early-stage HIV-1 infection.Journal of virology · 2025Article
- Soluble CD4 inhibits Ebola virus infection by targeting endosomal receptor-binding site.iScience · 2025Article
- Safety, pharmacokinetics, and biological activity of CD4-mimetic BNM-III-170 in SHIV-infected rhesus macaques.Journal of virology · 2025Article
- Viral glycoprotein-mediated entry and antibody-mediated immunity in HIV-1 and SARS-CoV-2 infection.Frontiers in immunology · 2025Review
- Article
- V3 tip determinants of susceptibility to inhibition by CD4-mimetic compounds in natural clade A human immunodeficiency virus (HIV-1) envelope glycoproteins.Journal of virology · 2023Article
- Outsmarting Pathogens with Antibody Engineering.Annual review of chemical and biomolecular engineering · 2023Review
- Temsavir blocks the immunomodulatory activities of HIV-1 soluble gp120.Cell chemical biology · 2023Article
- Piperidine CD4-Mimetic Compounds Expose Vulnerable Env Epitopes Sensitizing HIV-1-Infected Cells to ADCC.Viruses · 2023Article
- Indoline CD4-mimetic compounds mediate potent and broad HIV-1 inhibition and sensitization to antibody-dependent cellular cytotoxicity.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Piperidine CD4-mimetic compounds expose vulnerable Env epitopes sensitizing HIV-1-infected cells to ADCC.bioRxiv : the preprint server for biology · 2023Article
- Small CD4 mimetics sensitize HIV-1-infected macrophages to antibody-dependent cellular cytotoxicity.Cell reports · 2023Article
- Structural and Functional Characterization of Indane-Core CD4-Mimetic Compounds Substituted with Heterocyclic Amines.ACS medicinal chemistry letters · 2023Article
- HIV-1 Vpu restricts Fc-mediated effector functions in vivo.Cell reports · 2022Article
- Characterization of Human Immunodeficiency Virus (HIV-1) Envelope Glycoprotein Variants Selected for Resistance to a CD4-Mimetic Compound.Journal of virology · 2022Article
- SERINC5 Restricts HIV-1 Infectivity by Promoting Conformational Changes and Accelerating Functional Inactivation of Env.Viruses · 2022Article
- Detection of the HIV-1 Accessory Proteins Nef and Vpu by Flow Cytometry Represents a New Tool to Study Their Functional Interplay within a Single Infected CD4Journal of virology · 2022Article
- Article
- Modulating HIV-1 envelope glycoprotein conformation to decrease the HIV-1 reservoir.Cell host & microbe · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 7 institutions in 2 countries.
Navid MadaniDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA. navid_madani@dfci.harvard.edu.
Amy M PrinciottoDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
Linh MachCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA.
Shilei DingCentre de Recherche du CHUM, Montreal, QC, H2X 0A9, Canada.
Jérémie PrevostCentre de Recherche du CHUM, Montreal, QC, H2X 0A9, Canada.
Jonathan RichardCentre de Recherche du CHUM, Montreal, QC, H2X 0A9, Canada.
Bhavna HoraDepartment of Medicine, Department of Immunology, Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, 27710, USA.
Laura SutherlandDepartment of Medicine, Department of Immunology, Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, 27710, USA.
Connie A ZhaoDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
Brandon P ConnCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA.
Todd BradleyDepartment of Medicine, Department of Immunology, Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, 27710, USA.
M Anthony MoodyDepartment of Medicine, Department of Immunology, Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, 27710, USA.
Bruno MelilloDepartment of Chemistry, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Andrés FinziCentre de Recherche du CHUM, Montreal, QC, H2X 0A9, Canada.
Barton F HaynesDepartment of Medicine, Department of Immunology, Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, 27710, USA.
Amos B Smith IiiDepartment of Chemistry, University of Pennsylvania, Philadelphia, PA, 19104, USA. smithab@sas.upenn.edu.
Sampa SantraCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA.
Joseph SodroskiDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA. joseph_sodroski@dfci.harvard.edu.
Duke Medical Center · USBeth Israel Deaconess Medical Center · USDana-Farber Cancer Institute · USCentre Hospitalier de l’Université de Montréal · CAUniversité de Montréal · CAUniversity of Pennsylvania · USHarvard University · US
Funding
Virus biology scientific research support componentUM1AI100645 · NIAID · DUKE UNIVERSITY · PI HAYNES, BARTON F. · 2012 to 2018
$204.7MUnderstanding Envelope Function in HIV-1 Infection: The Design, Synthesis and Validation of Small Molecule HIV-1 Env InhibitorsP01GM056550 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI ABRAMS, CAMERON F · 1997 to 2018
$31.2MConformational Landscape of the HIV-1 Envelope GlycoproteinsR01AI124982 · NIAID · DANA-FARBER CANCER INST · PI SODROSKI, JOSEPH G · 2016 to 2025
$6.7MDesign of dendrimeric HIV-1 transmission inhibitors targeting gp120 Phe-43 cavityR56AI090682 · NIAID · DANA-FARBER CANCER INST · PI MADANI, NAVID · 2010 to 2010
$576kNIAID NIH HHS R01 AI124982NIAID NIH HHS R56 AI090682NIAID NIH HHS UM1 AI100645NIGMS NIH HHS P01 GM056550
Abstract
The envelope glycoprotein (Env) trimer ((gp120/gp41)
Indexed as
AIDS VaccinesAnimalsDrug Evaluation, PreclinicalGuanidinesHEK293 CellsHIV Envelope Protein gp120HumansImmunity, HeterologousImmunizationIndenesLentiviruses, PrimateMacaca mulattaAIDS VaccinesBNM-III-170gp120 protein, Human immunodeficiency virus 1GuanidinesHIV Envelope Protein gp120Indenes
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.